Therapeutic Outcomes and Prognostic Factors in Childhood Absence Epilepsy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Hye Ryun | - |
dc.contributor.author | Kim, Gun-Ha | - |
dc.contributor.author | Eun, So-Hee | - |
dc.contributor.author | Eun, Baik-Lin | - |
dc.contributor.author | Byeon, Jung Hye | - |
dc.date.accessioned | 2021-09-04T00:57:21Z | - |
dc.date.available | 2021-09-04T00:57:21Z | - |
dc.date.created | 2021-06-17 | - |
dc.date.issued | 2016-04 | - |
dc.identifier.issn | 1738-6586 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/89012 | - |
dc.description.abstract | Background and Purpose Childhood absence epilepsy (CAE) is one of the most common types of pediatric epilepsy. It is generally treated with ethosuximide (ESM), valproic acid (VPA), or lamotrigine (LTG), but the efficacy and adverse effects of these drugs remain controversial. This study compared initial therapy treatment outcomes, including VPA-LTG combination, and assessed clinical factors that may predict treatment response and prognosis. Methods Sixty-seven patients with typical CAE were retrospectively enrolled at the Korea University Medical Center. We reviewed patients' clinical characteristics, including age of seizure onset, seizure-free interval, duration of seizure-free period, freedom from treatment failure, breakthrough seizures frequency, and electroencephalogram (EEG) findings. Results The age at seizure onset was 7.9 +/- 2.7 years (mean +/- SD), and follow-up duration was 4.4 +/- 3.7 years. Initially, 22 children were treated with ESM (32.8%), 23 with VPA (34.3%), 14 with LTG (20.9%), and 8 with VPA-LTG combination (11.9%). After 48 months of therapy, the rate of freedom from treatment failure was significantly higher for the VPA-LTG combination therapy than in the three monotherapy groups (p=0.012). The treatment dose administrated in the VPA-LTG combination group was less than that in the VPA and LTG monotherapy groups. The shorter interval to loss of 3-Hz spike-and-wave complexes and the presence of occipital intermittent rhythmic delta activity on EEG were significant factors predicting good treatment response. Conclusions This study showed that low-dose VPA-LTG combination therapy has a good efficacy and fewer side effects than other treatments, and it should thus be considered as a first line therapy in absence epilepsy. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN NEUROLOGICAL ASSOC | - |
dc.subject | LONG-TERM PROGNOSIS | - |
dc.subject | VALPROIC ACID | - |
dc.subject | SODIUM VALPROATE | - |
dc.subject | LAMOTRIGINE | - |
dc.subject | SEIZURES | - |
dc.subject | ETHOSUXIMIDE | - |
dc.subject | MONOTHERAPY | - |
dc.subject | CHILDREN | - |
dc.title | Therapeutic Outcomes and Prognostic Factors in Childhood Absence Epilepsy | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Gun-Ha | - |
dc.contributor.affiliatedAuthor | Eun, So-Hee | - |
dc.contributor.affiliatedAuthor | Eun, Baik-Lin | - |
dc.contributor.affiliatedAuthor | Byeon, Jung Hye | - |
dc.identifier.doi | 10.3988/jcn.2016.12.2.160 | - |
dc.identifier.scopusid | 2-s2.0-84963625940 | - |
dc.identifier.wosid | 000373522500005 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL NEUROLOGY, v.12, no.2, pp.160 - 165 | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL NEUROLOGY | - |
dc.citation.title | JOURNAL OF CLINICAL NEUROLOGY | - |
dc.citation.volume | 12 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 160 | - |
dc.citation.endPage | 165 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002094827 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.subject.keywordPlus | LONG-TERM PROGNOSIS | - |
dc.subject.keywordPlus | VALPROIC ACID | - |
dc.subject.keywordPlus | SODIUM VALPROATE | - |
dc.subject.keywordPlus | LAMOTRIGINE | - |
dc.subject.keywordPlus | SEIZURES | - |
dc.subject.keywordPlus | ETHOSUXIMIDE | - |
dc.subject.keywordPlus | MONOTHERAPY | - |
dc.subject.keywordPlus | CHILDREN | - |
dc.subject.keywordAuthor | epilepsy | - |
dc.subject.keywordAuthor | absence seizures | - |
dc.subject.keywordAuthor | prognostic factors | - |
dc.subject.keywordAuthor | valproic acid | - |
dc.subject.keywordAuthor | lamotrigine | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.